Vesilute Peptide 20mg

Description

What Is Vesilute Peptide?

Vesilute peptide is a synthetic tripeptide bioregulator with the amino acid sequence Lys-Glu-Asp (KED), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Vesilute belongs to the Khavinson bioregulator peptides class — short regulatory peptides that modulate tissue-specific gene expression at physiological concentrations. Vesilute’s primary research targets are the urinary bladder wall and vascular endothelium, though it has also been studied for broader neuroprotective and anti-aging properties in preclinical gerontology models due to its effects on vascular smooth muscle and endothelial gene expression.

As a bladder bioregulator with vascular and neuroprotective research applications, vesilute operates through the Khavinson epigenetic mechanism — interacting with complementary DNA sequences in gene promoter regions to modulate transcription of tissue-specific genes involved in smooth muscle contractility, endothelial function, and age-related vascular decline. PrymaLab Vesilute 20mg is manufactured to high purity standards and supplied exclusively for qualified preclinical research.

Vesilute 20mg: Key Specifications

How Vesilute Works: Bioregulator Mechanism of Action

Vesilute operates through the Khavinson model of peptide bioregulation, modulating gene expression through direct peptide-DNA interaction in promoter regions of target genes. The KED tripeptide sequence has demonstrated affinity for DNA motifs enriched in genes governing smooth muscle contractility, endothelial nitric oxide regulation, and vascular wall homeostasis.

Vascular Endothelial Gene Modulation

Vesilute has been studied for its effects on endothelial cell gene expression, including genes regulating nitric oxide synthase (eNOS) activity, prostacyclin production, and vascular smooth muscle tone. In aged vascular tissue models, vesilute administration was associated with restoration of endothelial gene expression profiles that deteriorate with vascular aging — a process central to age-related cardiovascular and cerebrovascular decline. This vascular mechanism underlies vesilute’s emerging research interest as a neuroprotective agent, since cerebral vascular health is a primary determinant of neuronal survival and cognitive function during aging.

Bladder Smooth Muscle Function

The urinary bladder detrusor muscle is a highly specialized smooth muscle tissue whose contractile capacity and neural coordination decline progressively with aging. Vesilute has been studied in bladder tissue models for its effects on smooth muscle contractility gene expression, detrusor muscle functional markers, and the balance between muscarinic receptor signaling and beta-adrenergic relaxation pathways that govern bladder filling and voiding reflexes.

Neuroprotective and Anti-aging Properties

Vesilute’s vascular endothelial effects extend to neuroprotection through the cerebrovascular pathway. Age-related decline in cerebral blood vessel function reduces nutrient and oxygen delivery to neurons, contributing to cognitive decline and neurodegeneration. By modulating endothelial gene expression and supporting vascular tone regulation, vesilute has been investigated in research models examining whether vascular bioregulation can provide indirect neuroprotective effects in aging brain tissue — a research paradigm increasingly recognized as critical to understanding age-related cognitive decline.

Vesilute Peptide Benefits: What Research Shows

The following reflects published preclinical and gerontological literature. PrymaLab Vesilute 20mg is supplied exclusively for research purposes.

Vascular Function Restoration in Aging Models

Research from the Khavinson group reports that vesilute administration in aged animal models was associated with improved endothelial function markers, including enhanced nitric oxide-dependent vasodilation, reduced endothelial dysfunction indices, and normalization of vascular smooth muscle tone. These effects are attributed to restoration of endothelial gene expression patterns toward younger functional profiles.

Bladder Function Support

Preclinical studies have documented vesilute’s effects on age-related bladder dysfunction markers, including improved detrusor muscle contractility parameters, normalized voiding reflex indicators, and maintenance of bladder wall structural integrity in aged tissue models. These findings position vesilute as a unique bioregulator targeting an organ system — the urinary bladder — that significantly impacts quality of life during aging but receives limited research attention compared to cardiovascular or neurological systems.

Cerebrovascular and Neuroprotective Effects

Emerging research interest in vesilute centers on its indirect neuroprotective effects mediated through cerebrovascular health. Published data from gerontological models indicates improved cerebral blood flow parameters and reduced markers of vascular-mediated neuronal stress in aged animals treated with vascular bioregulator peptides. This cerebrovascular neuroprotection mechanism is distinct from direct neuronal bioregulators like cortagen, making vesilute relevant to complementary multi-organ bioregulation research protocols.

Vesilute vs. Cardiogen: Vascular Bioregulator Comparison

How to Store and Handle PrymaLab Vesilute 20mg

1. Store lyophilized at −20°C. Keep sealed, desiccated, and protected from light. Stable for 24+ months.
2. Allow vial to reach room temperature before opening to prevent condensation.
3. Reconstitute with appropriate sterile solvent (bacteriostatic water or sterile saline). Add slowly along vial wall.
4. Use reconstituted solution within 2–4 weeks. Refrigerate at 2–8°C and mark date.
5. Avoid repeated freeze-thaw cycles. Aliquot into single-use portions if needed.
6. Retain the Certificate of Analysis for lot traceability and documentation.

Why Choose PrymaLab Vesilute 20mg?

PrymaLab supplies Vesilute 20mg as a high-purity research-grade bioregulator peptide verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch ships with a unique lot number and Certificate of Analysis. Independent third-party testing ensures unbiased quality verification and full traceability for GLP-compliant research environments.

Frequently Asked Questions About Vesilute Peptide

What is vesilute peptide and what does it target?

Vesilute is a synthetic tripeptide bioregulator (Lys-Glu-Asp, KED) developed by Professor Khavinson that targets the bladder wall, vascular endothelium, and smooth muscle tissue. It belongs to the Khavinson bioregulator peptide class and has been studied for vascular function restoration, bladder support, and indirect neuroprotective effects via cerebrovascular health in preclinical aging research models.

How does vesilute provide neuroprotective effects?

Vesilute’s neuroprotective properties are mediated through its vascular endothelial effects rather than direct neuronal action. By restoring endothelial gene expression and supporting cerebrovascular function — including nitric oxide-dependent vasodilation and cerebral blood flow regulation — vesilute helps maintain the vascular delivery of oxygen and nutrients to brain tissue that declines during aging. This vascular neuroprotection mechanism is complementary to direct neuronal bioregulators like cortagen.

What is the difference between vesilute and cardiogen?

Both target the cardiovascular system but through different tissue types. Vesilute (KED) focuses on vascular endothelium and smooth muscle, supporting blood vessel function and bladder wall integrity. Cardiogen (AEDR) targets cardiac muscle (cardiomyocytes), focusing on heart tissue gene expression and cardiac function. Research protocols sometimes combine both for comprehensive cardiovascular system support.

How should vesilute be stored?

Store lyophilized vesilute at −20°C, desiccated and protected from light, for 24+ months stability. After reconstitution, refrigerate at 2–8°C and use within 2–4 weeks. Avoid repeated freeze-thaw cycles.

What purity does PrymaLab vesilute achieve?

PrymaLab Vesilute 20mg is verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch includes a Certificate of Analysis with independent third-party testing results for unbiased quality verification.

Research Disclaimer

For Research Use Only. PrymaLab Vesilute 20mg is intended exclusively for qualified preclinical research use. This product is not intended for human consumption, therapeutic use, veterinary treatment, or any application outside controlled research environments. Vesilute has not been approved by the FDA or any equivalent regulatory authority for therapeutic use. All research applications described are from published preclinical and gerontological literature. Researchers are responsible for regulatory compliance.